To evaluate the immunogenicity, clinical efficacy, and safety of prophylactic HPV vaccines in females. The assessment of clinical efficacy will address protection against HPV infection (for homologous and heterologous HPV types), against re-infection, against cervical cancer and its precursors (high-grade CIN (grade 2 or grade 3), adenocarcinoma in situ) in women previously not exposed to HPV infection (negative at enrolment for both HPV DNA and antibodies against the vaccine HPV types). We will assess clinical effectiveness by evaluating outcomes in all women, irrespective of the HPV DNA or serology status at enrolment. Evaluation by fine age and time since sexual debut categories is also planned.
Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors
30 December 2013
This Cochrane Review is at the protocol stage and there is no abstract or plain language summary. The objectives for the review are as follows:
More like this
- Interventions for encouraging sexual behaviours intended to prevent cervical cancer
- Women can experience high levels of anxiety at all stages of screening for cervical cancer including colposcopy
- Interventions to prevent blood loss during the treatment of pre-cancerous abnormalities in the cervix (cervical intraepithelial neoplasia).
- The use of retinoids (vitamin A derivatives) to prevent progression of cervical intra-epithelial neoplasia (CIN)
- No clear evidence to show any one optimal surgical technique is superior for treating pre-cancerous cervix abnormalities